<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.103047</article-id><article-id pub-id-type="publisher-id">TCM-42407</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210300000_41457533.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  心肌声学造影评价苓桂术甘汤颗粒剂型治疗冠心病的临床疗效
  Clinical Effect of Lingguizhugan Decoction Granule in the Treatment of Coronary Heart Disease Evaluated by Myocardial Contrast Echocardiography
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>景环</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>艳丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>欢</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆市江津区中医院，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>04</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>338</fpage><lpage>342</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨苓桂术甘汤颗粒剂型在冠心病治疗中的疗效。方法：将60例冠心病患者分为30例对照组及30例治疗组，对照组患者予冠心病西医标准治疗；治疗组患者予冠心病西医标准治疗联合苓桂术甘汤颗粒剂型治疗，60例冠心病患者治疗前及治疗后均行心肌声学造影检查，治疗30天后比较两组治疗疗效及心肌的血流量。结果：治疗后治疗组的中医证候积分减低(P = 0.014)，心肌的血流量增高(P = 0.021)，临床治疗总有效率增高(P = 0.001)。结论：苓桂术甘汤颗粒剂型降低了冠心病患者的中医证候积分，提高心肌血流量，为临床应用苓桂术甘汤颗粒剂型治疗冠心病提供了依据。
   Objective: To investigate the effect of Lingguizhugan Decoction granule in the treatment of co-ronary heart disease. Methods: 60 patients with coronary heart disease were divided into con-trol group (n = 30) and treatment group (n = 30). Patients in the control group received stan-dard western medicine treatment for coronary heart disease, and patients in the treatment group were treated with standard treatment of western medicine combined with granule dosage form of Lingguizhugan Decoction. Myocardial contrast acoustic examination was performed in all patients before and after treatment. After 30 days of treatment, the therapeutic efficacy and myocardial blood flow were compared between the two groups. Results: After treatment, the TCM syndrome score of the treatment group decreased (P = 0.014), the myocardial blood flow increased (P = 0.021), and the total effective rate of clinical treatment increased (P = 0.001). Conclusions: Lingguizhugan Decoction granule can reduce the TCM syndrome score of patients with coronary heart disease, improve myocardial blood flow, and this study may provide basis for clinical application of Lingguizhugan Decoction granule in the treatment of coronary heart disease.
 
</p></abstract><kwd-group><kwd>冠心病，苓桂术甘汤颗粒剂型，心肌声学造影，中医证候积分, Coronary Heart Disease</kwd><kwd> Granule Form of Lingguizhugan Decoction</kwd><kwd> Myocardial Contrast Acoustic</kwd><kwd> TCM Syndrome Integral</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨苓桂术甘汤颗粒剂型在冠心病治疗中的疗效。方法：将60例冠心病患者分为30例对照组及30例治疗组，对照组患者予冠心病西医标准治疗；治疗组患者予冠心病西医标准治疗联合苓桂术甘汤颗粒剂型治疗，60例冠心病患者治疗前及治疗后均行心肌声学造影检查，治疗30天后比较两组治疗疗效及心肌的血流量。结果：治疗后治疗组的中医证候积分减低(P = 0.014)，心肌的血流量增高(P = 0.021)，临床治疗总有效率增高(P = 0.001)。结论：苓桂术甘汤颗粒剂型降低了冠心病患者的中医证候积分，提高心肌血流量，为临床应用苓桂术甘汤颗粒剂型治疗冠心病提供了依据。</p></sec><sec id="s2"><title>关键词</title><p>冠心病，苓桂术甘汤颗粒剂型，心肌声学造影，中医证候积分</p></sec><sec id="s3"><title>Clinical Effect of Lingguizhugan Decoction Granule in the Treatment of Coronary Heart Disease Evaluated by Myocardial Contrast Echocardiography</title><p>Jinghuan Sun, Yanli Yuan, Huan Yang<sup>*</sup></p><p>Jiangjin Hospital of Traditional Chinese Medicine, Chongqing</p><p><img src="//html.hanspub.org/file/8-2270683x5_hanspub.png" /></p><p>Received: Mar. 29<sup>th</sup>, 2021; accepted: May 12<sup>th</sup>, 2021; published: May 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/8-2270683x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the effect of Lingguizhugan Decoction granule in the treatment of coronary heart disease. Methods: 60 patients with coronary heart disease were divided into control group (n = 30) and treatment group (n = 30). Patients in the control group received standard western medicine treatment for coronary heart disease, and patients in the treatment group were treated with standard treatment of western medicine combined with granule dosage form of Lingguizhugan Decoction. Myocardial contrast acoustic examination was performed in all patients before and after treatment. After 30 days of treatment, the therapeutic efficacy and myocardial blood flow were compared between the two groups. Results: After treatment, the TCM syndrome score of the treatment group decreased (P = 0.014), the myocardial blood flow increased (P = 0.021), and the total effective rate of clinical treatment increased (P = 0.001). Conclusions: Lingguizhugan Decoction granule can reduce the TCM syndrome score of patients with coronary heart disease, improve myocardial blood flow, and this study may provide basis for clinical application of Lingguizhugan Decoction granule in the treatment of coronary heart disease.</p><p>Keywords:Coronary Heart Disease, Granule Form of Lingguizhugan Decoction, Myocardial Contrast Acoustic, TCM Syndrome Integral</p><disp-formula id="hanspub.42407-formula56"><graphic xlink:href="//html.hanspub.org/file/8-2270683x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-2270683x8_hanspub.png" /> <img src="//html.hanspub.org/file/8-2270683x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>冠心病是常见的心血管疾病，严重威胁人类健康。冠状动脉造影是目前诊断冠心病较可靠的方法，但其不能反映患者心肌细胞的情况，且冠状动脉造影作为一种有创检查，可能会产生一些并发症 [<xref ref-type="bibr" rid="hanspub.42407-ref1">1</xref>]，无创、准确、可重复地诊断及评价冠心病疗效是目前研究的重点。研究发现心肌声学造影在诊断冠状动脉狭窄中应用价值较高，敏感性高 [<xref ref-type="bibr" rid="hanspub.42407-ref2">2</xref>]。本研究比较30例冠心病患者予以西医常规治疗及30例冠心病患者予以西医常规治疗联合服用苓桂术甘汤颗粒剂型治疗前后心肌的血流量(Myocardial blood flow, MBF)和中医证候积分的情况，探讨苓桂术甘汤颗粒剂型在临床治疗冠心病中的价值。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选择重庆市中医院及重庆市江津区中医院2018年8月至2019年12月诊断为冠心病的住院及门诊患者60例，其年龄、病程比较差异无统计学意义，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of the patients in two groups at baselin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >年龄(岁)</th><th align="center" valign="middle" >病程(年)</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >64.42 &#177; 2.11<sup>*</sup></td><td align="center" valign="middle" >8.54 &#177; 0.21<sup>*</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >63.34 &#177; 2.37</td><td align="center" valign="middle" >8.12 &#177; 0.23</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.2341</td><td align="center" valign="middle" >0.0863</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.4502</td><td align="center" valign="middle" >0.4532</td></tr></tbody></table></table-wrap><p>表1. 一般资料比较</p><p>注：与对照组比较，*表示P &gt; 0.05，差异无统计学意义。</p></sec><sec id="s6_2"><title>2.2. 纳入标准</title><p>①符合稳定性冠心病心绞痛的西医诊断标准，心绞痛分级程度分级为I级、II级和III级者；②每周心绞痛发作 ≥ 2次，但&lt;6次/d；③符合心血瘀阻证辨证；④年龄40~75岁，男女不限；⑤研究获得本院医学伦理委员审查、同意，并取得患者或家属签订的知情同意书。</p></sec><sec id="s6_3"><title>2.3. 排除标准</title><p>①不稳定性心绞痛患者；②半年内有发生急性心肌梗塞者或有血管重建史，有重度心律失常者，重度心肺功能不全者；③重度神经官能症、颈椎病、更年期症候群等所致胸痛者；④过敏体质或对多种药物过敏者；⑤妊娠期和哺乳期妇女；⑥合并肝、肾、造血及代谢系统严重原发性疾病、合并有肺炎或严重全身感染者。</p></sec><sec id="s6_4"><title>2.4. 脱落及剔除标准</title><p>签署知情同意书，符合纳入标准，并经随机化分组的受试者，在治疗中出现下列情况之一者，作为脱落及剔除处理：发生严重并发症；出现严重不良反应；依从性差；自愿放弃治疗；重要资料不全。</p></sec><sec id="s6_5"><title>2.5. 治疗方法</title><p>将60例患者随机分为治疗组30例，对照组30例。对照组：按《慢性稳定性冠心病诊断与治疗指南》方法进行治疗。口服阿司匹林肠溶片0.1g/次，1次/d；琥珀酸美托洛尔23.75~47.5 mg，1次/d；贝那普利10 mg，1次/d；阿托伐他汀20 mg，1次/d；盐酸曲美他嗪片20 mg/次，3次/d；对高血压和糖尿病患者给予对症处理。急救用药：硝酸甘油片，必要时使用，舌下含服，0.5 mg/片。治疗组：西药治疗同对照组，并加用苓桂术甘汤颗粒剂型，药物组成：茯苓15 g、桂枝12 g、炒白术12 g、炙甘草6 g，(北京康仁堂药业有限公司)。每天1剂，分早晚2次，温开水冲服。两组用药疗程均为30天。治疗期间因本病死亡者统计时视为效果相反，即反效；与本病无关的死亡，中途自行退出研究者视为无效病例。</p></sec><sec id="s6_6"><title>2.6. 主要观察指标</title><sec id="s6_6_1"><title>2.6.1. 中医临床证候积分和临床疗效评定</title><p>参照《中药新药临床研究指导原则》将症状分四级为：无、轻、中及重，分别记为0分、1分、2分及3分，症状包括胸闷痛、气冲心感、气短、心悸、遇寒加重、舌象、脉象等，根据总分评价疗效。临床疗效评定分为四级。显效：减少70%以上的中医症状积分；有效：减少30%~70%的中医症状积分；无效：减少30%以下的中医症状积分；反效：治疗后较治疗前增加了中医症状积分。显效和有效的总和，除去总观察数，为总有效率。观察对象在治疗前和后各进行1次中医症状积分评定。</p></sec><sec id="s6_6_2"><title>2.6.2. 超声心动图检查</title><p>选用具有心肌造影成像模式的彩色多普勒超声诊断仪Philip EPIQ，S5-1心脏探头，声学造影剂SonoVue (声诺维)用生理盐水5毫升稀释，得到白色乳状微泡悬液后，经左肘静脉通路2毫升快速推注，继以5毫升生理盐水推注声学造影剂，图像采集后选取有效的病变冠状动脉的显像节段，使用实时MCE软件进行分析，将感兴趣区置于病变节段的室壁中央,得出心肌时间-强度曲线，收集60例患者治疗前及治疗后30天的心肌的血流量值。</p></sec></sec><sec id="s6_7"><title>2.7. 统计学处理</title><p>运用SPSS 19.0进行数据分析，计量资料用均数&#177;标准差( x &#175; &#177; s )表示，组间显著性比较用t检验；计数资料用率表示，率的比较用c<sup>2</sup>检验，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>1、治疗组和对照组中医证候积分的比较，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> TCM syndrome scores of treatment group and control group ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前(分)</th><th align="center" valign="middle" >治疗后(分)</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >20.76 &#177; 3.91</td><td align="center" valign="middle" >8.71 &#177; 3.45</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >20.51 &#177; 4.18</td><td align="center" valign="middle" >14.21 &#177; 3.91</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.621</td><td align="center" valign="middle" >0.014</td></tr></tbody></table></table-wrap><p>表2. 治疗组和对照组中医证候积分的比较( x &#175; &#177; s )</p><p>注：治疗前两组比较，P &gt; 0.05；治疗后两组比较，P &lt; 0.05。</p><p>2、治疗组和对照组临床疗效比较，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Clinical efficacy of treatment group and control group (n, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数(n)</th><th align="center" valign="middle" >显效</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >加重</th><th align="center" valign="middle" >总有效率(%)</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >93.33</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >76.67</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001</td></tr></tbody></table></table-wrap><p>表3. 治疗组和对照组临床疗效的比较(n, %)</p><p>注：与对照组比较，治疗组的总有效率优于对照组，P &lt; 0.05。</p><p>3、治疗组和对照组MBF比较，见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> MBF in treatment group and control group ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前(dB/s)</th><th align="center" valign="middle" >治疗后(dB/s)</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >2.24 &#177; 0.71</td><td align="center" valign="middle" >3.57 &#177; 0.67</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >2.15 &#177; 0.61</td><td align="center" valign="middle" >2.91 &#177; 0.69</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.715</td><td align="center" valign="middle" >0.021</td></tr></tbody></table></table-wrap><p>表4. 治疗组和对照组MBF的比较( x &#175; &#177; s )</p><p>注：治疗前两组比较，P &gt; 0.05；治疗后两组比较，P &lt; 0.05。</p></sec><sec id="s8"><title>4. 讨论</title><p>超声心动图是诊断冠心病的常用影像学手段之一 [<xref ref-type="bibr" rid="hanspub.42407-ref3">3</xref>]，MCE可早期定量评估节段增厚心肌及相邻心肌微循环功能 [<xref ref-type="bibr" rid="hanspub.42407-ref4">4</xref>]，可评价局部及整体心肌灌注 [<xref ref-type="bibr" rid="hanspub.42407-ref5">5</xref>]，心肌灌注状态与心脏整体功能的恢复存在一定的关联，大大提高了超声技术对心肌整体及局部的功能评估的可靠性。</p><p>现代医学防治冠心病取得了长足进步，药物、介入及外科手术等方法日趋成熟，但临床仍然有大量患者难以得到有效治疗，中医药防治冠心病近年来已获得大量成果与突破 [<xref ref-type="bibr" rid="hanspub.42407-ref6">6</xref>]。冠心病属于中医学“心痛”、“胸痹”等范畴。《灵枢&#183;阴阳系日月》曰：“心为阳中之太阳”。心属火，上居于胸，能行阳令而制阴于下。心的温煦、推动功能在人体生命活动中发挥着重要作用。心阳充沛，与其他脏腑间的通道畅通，五脏六腑之功能亦可维持正常。正如《金匮要略论注》中指出：“今阳微知虚在上焦，其所以胸痹心痛”。故治疗上以扶阳活血为法。苓桂术甘汤出自《伤寒杂病论》，《伤寒论&#183;辨太阳病脉证并治中第六》第67条：“伤寒若吐若下后，心下逆满，气上冲胸，起则头眩，脉沉紧，发汗则动经，身为振振摇者，茯苓桂枝白术甘草汤主之”。《金匮要略&#183;痰饮咳嗽病脉证并治第十二》第16、17条：“心下有痰饮，胸胁支满，目眩，苓桂术甘汤主之”，“夫短气有微饮，当从小便去之，苓桂术甘汤主之”。所以本方的病机可以总结为阳气亏虚，水气上冲。方中茯苓为君，化痰消饮；桂枝为臣，温阳平冲；苓、桂相合为温阳化饮，利水平冲之常用组合。白术为佐，健脾制饮。甘草为使，助桂枝温阳、助白术制饮、调和作用。</p><p>本研究发现治疗组及对照组患者治疗前的中医症状积分、心肌的血流量无明显统计学差异(P &gt; 0.05)，与治疗后对照组比较，治疗后治疗组的中医证候积分减低，心肌的血流量增高，临床治疗总有效率增高(P &lt; 0.05)，具有统计学意义，说明苓桂术甘汤颗粒剂型在治疗冠心病患者中具有一定的价值。</p></sec><sec id="s9"><title>基金项目</title><p>重庆市江津区科委攻关项目(Y2018006)。</p></sec><sec id="s10"><title>文章引用</title><p>孙景环,袁艳丽,杨 欢. 心肌声学造影评价苓桂术甘汤颗粒剂型治疗冠心病的临床疗效Clinical Effect of Lingguizhugan Decoction Granule in the Treatment of Coronary Heart Disease Evaluated by Myocardial Contrast Echocardiography[J]. 中医学, 2021, 10(03): 338-342. https://doi.org/10.12677/TCM.2021.103047</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42407-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">何艳琴. 冠状动脉造影术六种并发症及预防策略[J]. 临床误诊误治, 2019, 32(2): 117.</mixed-citation></ref><ref id="hanspub.42407-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">吴美善, 李江华, 刘霞, 等. 心肌声学造影对冠状动脉狭窄临界病变功能性评价的有效性及可靠性分析[J]. 中西医结合心脑血管病杂志, 2021,19(3): 461-463.</mixed-citation></ref><ref id="hanspub.42407-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">陈敬霞, 陆兆游, 陈浩刚. 超声心动图联合心电图对冠心病诊断的临床意义[J]. 影像研究与医学应用, 2021, 5(3): 26-27+36.</mixed-citation></ref><ref id="hanspub.42407-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">刘学兵, 邓燕, 李赵欢, 等. 心肌声学造影定量评估节段增厚心肌微循环功能[J]. 临床超声医学杂志, 2020, 22(11): 834-837.</mixed-citation></ref><ref id="hanspub.42407-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">王琴, 吴丹, 刘霞, 等. 心肌声学造影评价心脏损害的应用进展[J]. 影像研究与医学应用, 2020, 4(14): 6-9.</mixed-citation></ref><ref id="hanspub.42407-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">廖江铨, 史载祥, 杜金行. 中医药防治冠心病现代研究进展及思考[J]. 中华中医药杂志, 2018, 33(11): 4813-4816.</mixed-citation></ref></ref-list></back></article>